In other words, covid-19 vaccines will neutralize your immune system therefore making you subjectable to other diseases.
PMID: 33113270
PMCID: PMC7645850
DOI: 10.1111/ijcp.13795
Aims of the study: Patient comprehension is a critical part of meeting medical ethics standards of informed consent in study designs. The aim of the study was to determine if sufficient literature exists to require clinicians to disclose the specific risk that COVID-19 vaccines could worsen disease upon exposure to challenge or circulating virus.
Methods used to conduct the study: Published literature was reviewed to identify preclinical and clinical evidence that COVID-19 vaccines could worsen disease upon exposure to challenge or circulating virus. Clinical trial protocols for COVID-19 vaccines were reviewed to determine if risks were properly disclosed.
Results of the study: COVID-19 vaccines designed to elicit neutralising antibodies may sensitise vaccine recipients to more severe disease than if they were not vaccinated. Vaccines for SARS, MERS and RSV have never been approved, and the data generated in the development and testing of these vaccines suggest a serious mechanistic concern: that vaccines designed empirically using the traditional approach (consisting of the unmodified or minimally modified coronavirus viral spike to elicit neutralising antibodies), be they composed of protein, viral vector, DNA or RNA and irrespective of delivery method, may worsen COVID-19 disease via antibody-dependent enhancement (ADE). This risk is sufficiently obscured in clinical trial protocols and consent forms for ongoing COVID-19 vaccine trials that adequate patient comprehension of this risk is unlikely to occur, obviating truly informed consent by subjects in these trials.
Conclusions drawn from the study and clinical implications: The specific and significant COVID-19 risk of ADE should have been and should be prominently and independently disclosed to research subjects currently in vaccine trials, as well as those being recruited for the trials and future patients after vaccine approval, in order to meet the medical ethics standard of patient comprehension for informed consent.
Similar articles
The effectiveness of health literacy interventions on the informed consent process of health care users: a systematic review protocol.Perrenoud B, Velonaki VS, Bodenmann P, Ramelet AS.JBI Database System Rev Implement Rep. 2015 Oct;13(10):82-94. doi: 10.11124/jbisrir-2015-2304.PMID: 26571285
ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.Alharbi NK, Padron-Regalado E, Thompson CP, Kupke A, Wells D, Sloan MA, Grehan K, Temperton N, Lambe T, Warimwe G, Becker S, Hill AVS, Gilbert SC.Vaccine. 2017 Jun 27;35(30):3780-3788. doi: 10.1016/j.vaccine.2017.05.032. Epub 2017 Jun 1.PMID: 28579232 Free PMC article.
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.Eckhardt CM, Cummings MJ, Rajagopalan KN, Borden S, Bitan ZC, Wolf A, Kantor A, Briese T, Meyer BJ, Jacobson SD, Scotto D, Mishra N, Philip NM, Stotler BA, Schwartz J, Shaz B, Spitalnik SL, Eisenberger A, Hod EA, Justman J, Cheung K, Lipkin WI, O'Donnell MR.Trials. 2020 Jun 8;21(1):499. doi: 10.1186/s13063-020-04422-y.PMID: 32513308 Free PMC article.
A review on Promising vaccine development progress for COVID-19 disease.Belete TM.Vacunas. 2020 Jul-Dec;21(2):121-128. doi: 10.1016/j.vacun.2020.05.002. Epub 2020 Jun 13.PMID: 32837460 Free PMC article. Review.
Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development.Ita K.Arch Med Res. 2020 Sep 10:S0188-4409(20)31154-1. doi: 10.1016/j.arcmed.2020.09.010. Online ahead of print.PMID: 32950264 Review.
Comments